Biotech company OKYO Pharma closes US$2.5 million IPO

biotechnology company OKYO Pharma Limited (Nasdaq: OKYO) closed its IPO on the Nasdaq Capital Market on Thursday. The company was able to raise around US$2.5 million in its debut on the big board.

The offering consisted of 625,000 US Depository Shares at US$4.00 per share. The company’s shares trade under the symbol “OKYO”.

Proceeds from the offering are intended to advance the Company’s OK-101 drug candidate for Investigational New Drug (IND) filing, funding for the drug’s Phase 2 clinical trial, as well as working capital and other general corporate purposes.

ThinkEquity acted as sole bookrunner for said offering.

The London-based life sciences company focuses on treating patients with inflammatory eye disease and eye pain. It is currently developing its lead preclinical product candidate OK-101 to treat dry eye disease.

OKYO Pharma last traded at US$3.00 on the Nasdaq.

Information for this briefing was found via Edgar and the companies mentioned. The author has no security or affiliation related to this organization. Not a buy or sell recommendation. Always do additional research and consult a professional before purchasing a title. The author holds no license.

Comments are closed.